ER7 Fundamental Analysis - ERAMET

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ER7. ER7 was compared to 40 industry peers in the Metals & Mining industry. ER7 may be in some trouble as it scores bad on both profitability and health. ER7 has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

ER7 had negative earnings in the past year.

ER7 had a negative operating cash flow in the past year.

Of the past 5 years ER7 4 years were profitable.

ER7 had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

With a Return On Assets value of -1.58%, ER7 is not doing good in the industry: 70.00% of the companies in the same industry are doing better.

The Return On Equity of ER7 (-9.29%) is worse than 75.00% of its industry peers.

ER7 has a Return On Invested Capital of 0.80%. This is in the lower half of the industry: ER7 underperforms 75.00% of its industry peers.

Measured over the past 3 years, the Average Return On Invested Capital for ER7 is in line with the industry average of 7.31%.

The 3 year average ROIC (7.29%) for ER7 is well above the current ROIC(0.80%). The reason for the recent decline needs to be investigated.

		Industry Rank	Sector Rank
ROA	-1.58%
ROE	-9.29%
ROIC	0.8%

ROA(3y)4.1%

ROA(5y)1.33%

ROE(3y)16.44%

ROE(5y)-1.91%

ROIC(3y)7.29%

ROIC(5y)7.73%

1.3 Margins

ER7's Profit Margin has declined in the last couple of years.

ER7's Operating Margin of 1.91% is on the low side compared to the rest of the industry. ER7 is outperformed by 67.50% of its industry peers.

ER7's Operating Margin has declined in the last couple of years.

With an excellent Gross Margin value of 68.15%, ER7 belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.

ER7's Gross Margin has improved in the last couple of years.

		Industry Rank	Sector Rank
OM	1.91%
PM (TTM)	N/A
GM	68.15%

OM growth 3Y-46.5%

OM growth 5Y-18.83%

PM growth 3Y-61.12%

PM growth 5YN/A

GM growth 3Y-3.21%

GM growth 5Y23.96%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ER7 is destroying value.

Compared to 1 year ago, ER7 has more shares outstanding

Compared to 5 years ago, ER7 has more shares outstanding

Compared to 1 year ago, ER7 has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of 1.08, we must say that ER7 is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of 1.08, ER7 is not doing good in the industry: 75.00% of the companies in the same industry are doing better.

A Debt/Equity ratio of 2.03 is on the high side and indicates that ER7 has dependencies on debt financing.

With a Debt to Equity ratio value of 2.03, ER7 is not doing good in the industry: 90.00% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	2.03
Debt/FCF	N/A
Altman-Z	1.08

ROIC/WACC0.09

WACC9.26%

2.3 Liquidity

A Current Ratio of 1.54 indicates that ER7 should not have too much problems paying its short term obligations.

Looking at the Current ratio, with a value of 1.54, ER7 is doing worse than 70.00% of the companies in the same industry.

ER7 has a Quick Ratio of 1.06. This is a normal value and indicates that ER7 is financially healthy and should not expect problems in meeting its short term obligations.

ER7 has a worse Quick ratio (1.06) than 60.00% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.54
Quick Ratio	1.06

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ER7 have decreased strongly by -221.18% in the last year.

Measured over the past years, ER7 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -64.00% on average per year.

The Revenue has decreased by -6.91% in the past year.

Measured over the past years, ER7 shows a decrease in Revenue. The Revenue has been decreasing by -4.39% on average per year.

EPS 1Y (TTM)-221.18%

EPS 3Y-64%

EPS 5YN/A

EPS Q2Q%-268.75%

Revenue 1Y (TTM)-6.91%

Revenue growth 3Y-7.18%

Revenue growth 5Y-4.39%

Sales Q2Q%-3.31%

3.2 Future

ER7 is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -44.51% yearly.

The Revenue is expected to grow by 7.00% on average over the next years.

EPS Next Y-340.43%

EPS Next 2Y-74.62%

EPS Next 3Y-44.51%

EPS Next 5YN/A

Revenue Next Year-0.95%

Revenue Next 2Y5.78%

Revenue Next 3Y7%

Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ER7 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ER7 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

62.50% of the companies in the same industry are cheaper than ER7, based on the Enterprise Value to EBITDA ratio.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	14.81

4.3 Compensation for Growth

ER7's earnings are expected to decrease with -44.51% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-74.62%

EPS Next 3Y-44.51%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 2.53%, ER7 has a reasonable but not impressive dividend return.

Compared to an average industry Dividend Yield of 1.95, ER7 pays a bit more dividend than its industry peers.

Compared to an average S&P500 Dividend Yield of 2.00, ER7 pays a bit more dividend than the S&P500 average.

		Industry Rank	Sector Rank
Dividend Yield	2.53%

5.2 History

Dividend Growth(5Y)N/A

Div Incr Years0

Div Non Decr Years1

5.3 Sustainability

ER7 has negative earnings and hence a negative payout ratio. The dividend may be in danger.

DP-44.33%

EPS Next 2Y-74.62%

EPS Next 3Y-44.51%

More info and screens

Find the best dividend stocks

Show peers with best dividend

ERAMET

FRA:ER7 (12/23/2025, 7:00:00 PM)

53.35

+0.45 (+0.85%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryMetals & Mining

Earnings (Last)10-30 2025-10-30

Earnings (Next)02-17 2026-02-17/amc

Inst Owners15.59%

Inst Owner ChangeN/A

Ins Owners0.17%

Ins Owner ChangeN/A

Market Cap1.53B

Revenue(TTM)2.88B

Net Income(TTM)-97.00M

Analysts52.73

Price Target53.14 (-0.39%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	2.53%

Yearly Dividend1.51

Dividend Growth(5Y)N/A

DP-44.33%

Div Incr Years0

Div Non Decr Years1

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)2.15%

PT rev (3m)-7.36%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-18.65%

EPS NY rev (3m)-30.76%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-5.57%

Revenue NY rev (3m)-6.66%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.53
P/FCF	N/A
P/OCF	N/A
P/B	1.47
P/tB	2.84
EV/EBITDA	14.81

EPS(TTM)-3.44

EYN/A

EPS(NY)-4.4

Fwd EYN/A

FCF(TTM)-25.76

FCFYN/A

OCF(TTM)-4.59

OCFYN/A

SpS100.31

BVpS36.3

TBVpS18.78

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-1.58%
ROE	-9.29%
ROCE	1.16%
ROIC	0.8%
ROICexc	0.95%
ROICexgc	1.09%
OM	1.91%
PM (TTM)	N/A
GM	68.15%
FCFM	N/A

ROA(3y)4.1%

ROA(5y)1.33%

ROE(3y)16.44%

ROE(5y)-1.91%

ROIC(3y)7.29%

ROIC(5y)7.73%

ROICexc(3y)10.98%

ROICexc(5y)11.38%

ROICexgc(3y)12.91%

ROICexgc(5y)13.43%

ROCE(3y)10.76%

ROCE(5y)11.32%

ROICexgc growth 3Y-56.22%

ROICexgc growth 5Y-25.38%

ROICexc growth 3Y-55.33%

ROICexc growth 5Y-24.94%

OM growth 3Y-46.5%

OM growth 5Y-18.83%

PM growth 3Y-61.12%

PM growth 5YN/A

GM growth 3Y-3.21%

GM growth 5Y23.96%

F-Score2

Asset Turnover0.47

Health

		Industry Rank	Sector Rank
Debt/Equity	2.03
Debt/FCF	N/A
Debt/EBITDA	10.29
Cap/Depr	403.31%
Cap/Sales	21.11%
Interest Coverage	0.34
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.54
Quick Ratio	1.06
Altman-Z	1.08

F-Score2

WACC9.26%

ROIC/WACC0.09

Cap/Depr(3y)260.42%

Cap/Depr(5y)209.27%

Cap/Sales(3y)18.57%

Cap/Sales(5y)15.29%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-221.18%

EPS 3Y-64%

EPS 5YN/A

EPS Q2Q%-268.75%

EPS Next Y-340.43%

EPS Next 2Y-74.62%

EPS Next 3Y-44.51%

EPS Next 5YN/A

Revenue 1Y (TTM)-6.91%

Revenue growth 3Y-7.18%

Revenue growth 5Y-4.39%

Sales Q2Q%-3.31%

Revenue Next Year-0.95%

Revenue Next 2Y5.78%

Revenue Next 3Y7%

Revenue Next 5YN/A

EBIT growth 1Y-51.75%

EBIT growth 3Y-50.34%

EBIT growth 5Y-22.39%

EBIT Next Year8.9%

EBIT Next 3Y30.86%

EBIT Next 5YN/A

FCF growth 1Y-850%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-121.46%

OCF growth 3YN/A

OCF growth 5YN/A

ERAMET / ER7.DE FAQ

What is the fundamental rating for ER7 stock?

ChartMill assigns a fundamental rating of 2 / 10 to ER7.DE.

What is the valuation status for ER7 stock?

ChartMill assigns a valuation rating of 0 / 10 to ERAMET (ER7.DE). This can be considered as Overvalued.

What is the profitability of ER7 stock?

ERAMET (ER7.DE) has a profitability rating of 3 / 10.

How financially healthy is ERAMET?

The financial health rating of ERAMET (ER7.DE) is 1 / 10.

Can you provide the dividend sustainability for ER7 stock?

The dividend rating of ERAMET (ER7.DE) is 3 / 10 and the dividend payout ratio is -44.33%.

ERAMET (ER7.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens

ERAMET / ER7.DE FAQ

What is the fundamental rating for ER7 stock?

What is the valuation status for ER7 stock?

What is the profitability of ER7 stock?

How financially healthy is ERAMET?

Can you provide the dividend sustainability for ER7 stock?